Literature DB >> 9020045

Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells.

K F Pirollo1, Z Hao, A Rait, C W Ho, E H Chang.   

Abstract

A signal transduction pathway, involving oncogenes and their normal counterparts the proto-oncogenes, analogous to that for cell growth and differentiation has been proposed to lead to the phenotype of cellular radioresistance (RR). In this report we provide evidence demonstrating the existence of such a pathway by using antisense oligonucleotides (ASO) to reverse the RR phenotype. Utilizing ASO directed against the raf-1 gene, a central component of this proposed pathway, we were able to reverse the RR phenotype of human tumor cell lines having elevated HER-2 expression or a mutant form of Ha-ras, two genes upstream of raf-1 in signal transduction. Additionally, anti-ras ASO were able to radiosensitize HER-2 overexpressing cells. These results, which verify the presence of a signaling pathway leading to cellular RR, also have possible clinical implications for the use of ASO as a means to sensitize radioresistant tumors to radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9020045     DOI: 10.1006/bbrc.1996.5922

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

2.  Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

Authors:  Maria J Sambade; Eldon C Peters; Nancy E Thomas; William K Kaufmann; Randall J Kimple; Janiel M Shields
Journal:  Radiother Oncol       Date:  2011-02-04       Impact factor: 6.280

3.  The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.

Authors:  Younghyun Lee; Huizi Keiko Li; Aya Masaoka; Shigeaki Sunada; Hirokazu Hirakawa; Akira Fujimori; Jac A Nickoloff; Ryuichi Okayasu
Journal:  Radiother Oncol       Date:  2016-09-22       Impact factor: 6.280

4.  Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.

Authors:  L Stingl; T Stühmer; M Chatterjee; M R Jensen; M Flentje; C S Djuzenova
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

5.  Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.

Authors:  Claire Marie-Elisabeth Sauvageot; Jessica Leigh Weatherbee; Santosh Kesari; Susan Elizabeth Winters; Jessica Barnes; Jamie Dellagatta; Naren Raj Ramakrishna; Charles Dean Stiles; Andrew Li-Jen Kung; Mark W Kieran; Patrick Yung Chih Wen
Journal:  Neuro Oncol       Date:  2008-08-05       Impact factor: 12.300

6.  Preclinical evaluation of radiosensitizing activity of Pluronic block copolymers.

Authors:  Reshani H Perera; Ravi Patel; Hanping Wu; Mihika Gangolli; Bryan Traughber; Nancy Oleinick; Agata A Exner
Journal:  Int J Radiat Biol       Date:  2013-06-03       Impact factor: 2.694

Review 7.  Molecular targets for tumor radiosensitization.

Authors:  Philip J Tofilon; Kevin Camphausen
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

8.  The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution.

Authors:  Frédérique Mégnin-Chanet; François Lavelle; Vincent Favaudon
Journal:  BMC Pharmacol       Date:  2002-02-06

9.  Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990.

Authors:  Dušan Milanović; Elke Firat; Anca Ligia Grosu; Gabriele Niedermann
Journal:  Radiat Oncol       Date:  2013-02-28       Impact factor: 3.481

Review 10.  Apoptosis and molecular targeting therapy in cancer.

Authors:  Mohamed Hassan; Hidemichi Watari; Ali AbuAlmaaty; Yusuke Ohba; Noriaki Sakuragi
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.